The estimated Net Worth of Kush Parmar is at least $47 Milion dollars as of 29 December 2020. Kush Parmar owns over 470,000 units of Homology Medicines Inc stock worth over $913,681 and over the last 8 years he sold FIXX stock worth over $45,822,163. In addition, he makes $262,648 as Independent Director at Homology Medicines Inc.
Sign up
Kush Parmar FIXX stock SEC Form 4 insiders trading
Kush has made over 8 trades of the Homology Medicines Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 470,000 units of FIXX stock worth $8,460,000 on 29 December 2020.
The largest trade he's ever made was selling 615,000 units of Homology Medicines Inc stock on 16 May 2019 worth over $13,204,050. On average, Kush trades about 122,928 units every 32 days since 2016. As of 29 December 2020 he still owns at least 982,453 units of Homology Medicines Inc stock.
You can see the complete history of Kush Parmar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kush Parmar biography
Dr. Kush M. Parmar M.D. serves as Independent Director of the Company. He is the Independent Director of the company. Dr. Parmar is a Managing Partner at 5AM Venture Management LLC, an early stage venture capital firm focused on the life sciences, where he has been since 2010. Before joining 5AM, from 2002 to 2010, he was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. physician scientist fellow in the joint Harvard-MIT Health Sciences and Technology Program. Dr. Parmar currently serves on the boards of numerous private companies. He previously served as a board member or observer for Arvinas, Inc., Achaogen, Inc., Audentes Therapeutics, Inc. (acquired by Astellas Pharma Inc.), Pulmatrix, Inc. and scPharmaceuticals Inc. He is a member of the scientific advisory boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation, and is a fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals, attended courses at Harvard Business School and consulted for an oncology startup. He also founded a non-profit international development organization, the Cruz Blanca Initiative. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School. Parmar’s experience in the life sciences industry,
What is the salary of Kush Parmar?
As the Independent Director of Homology Medicines Inc, the total compensation of Kush Parmar at Homology Medicines Inc is $262,648. There are 8 executives at Homology Medicines Inc getting paid more, with Arthur Tzianabos having the highest compensation of $5,062,880.
How old is Kush Parmar?
Kush Parmar is 39, he's been the Independent Director of Homology Medicines Inc since 2015. There are 18 older and no younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.
What's Kush Parmar's mailing address?
Kush's mailing address filed with the SEC is 2400 District Ave #310, Burlington, MA 01803, USA.
Insiders trading at Homology Medicines Inc
Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management... oraz Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.
What does Homology Medicines Inc do?
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
What does Homology Medicines Inc's logo look like?
Complete history of Kush Parmar stock trades at scPharmaceuticals Inc, Homology Medicines Inc, Arvinas Inc oraz Akouos
Homology Medicines Inc executives and stock owners
Homology Medicines Inc executives and other stock owners filed with the SEC include:
-
Arthur Tzianabos,
President, Chief Executive Officer, Director -
Tim Kelly,
Chief Technical Operations Officer -
Albert Seymour,
Chief Scientific Officer -
W. Bradford Smith,
Chief Financial Officer, Treasurer and Secretary -
Dr. Arthur O. Tzianabos Ph.D.,
Pres, CEO & Director -
Dr. Albert Seymour Ph.D.,
Chief Scientific Officer -
W. Bradford Smith CPA, M.B.A.,
CFO & Treasurer -
Alise Reicin,
Independent Director -
Kush Parmar,
Independent Director -
Mary Thistle,
Independent Director -
Richard Gregory,
Independent Director -
Matthew Patterson,
Independent Director -
Steven Gillis,
Independent Director -
Jeffrey Poulton,
Director -
Gabriel Cohn,
Chief Medical Officer -
Cara Mayfield,
Director of Corp. Communications -
Dr. Deborah Kinch Ph.D.,
Chief Devel. Officer -
Dr. Julie Jordan M.D.,
Sr. VP and Head of Clinical Devel. & Operations -
Michael Blum M.B.A.,
Chief Commercial Officer -
Dr. Gabriel M. Cohn M.B.A., M.D.,
Chief Medical Officer -
Melissa Gelormini,
VP of HR -
Theresa McNeely,
Chief Communications Officer & Patient Advocate -
Dr. Paul Alloway J.D., Ph.D.,
Chief Legal Officer & Sec. -
Timothy P. Kelly M.B.A.,
Chief Operating Officer -
Dr. Saswati Chatterjee Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Ventures Iv, L.P.5 Am Co In...,
-
Ventures Iv, L.P.5 Am Partn...,
-
Institutes For Bio Medical ...,
-
Ventures, Llcvv Manager Llc...,
-
Holdings (Private) Ltd Full...,
-
Cameron Wheeler,
Director -
Siyamak Rasty,
Chief Operating Officer -
James Edeerfield Management...,
-
James Edeerfield Management...,
-
Venture Fund Viii, L.P.Arch...,
-
Springs Capital Management ...,
-
Venture Fund Viii, L.P.Arch...,
-
Charles Jr Michaud,
See Remarks -
Paul Alloway,
See Remarks -
Michael Lee Blum,
Chief Commercial Officer -
Julie Jordan,
Chief Medical Officer